Saturday, June 25, 2022
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home Headlines

WHO to decide on emergency usage of Bharat Biotech’s Covaxin

by Digital Desk
9 months ago
in Headlines, International
A A
WHO to decide on emergency usage of Bharat Biotech’s Covaxin
Share on FacebookShare on Twitter

New Delhi : The World Health Organisation (WHO) on Wednesday informed that the final decision on Bharat Biotech’s submission on emergency use listing (EUL) for its Covaxin COVID-19 vaccine will be made in October 2021.

The status of assessment for Covaxin is “ongoing” as of now, the WHO informed in a document citing the status of COVID vaccines. On the WHO website, the decision date for Bharat Biotech’s Covaxin is October 2021.

Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine. The duration of the emergency use listing process depends on the quality of the data which is submitted by the vaccine manufacturer. The WHO has also asked for additional data from Bharat Biotech for Covaxin, sources from the WHO informed media.

“There is a procedure of submitting the documents for approval, WHO’s emergency use authorization to Covaxin is expected soon,” Dr Bharati Pravin Pawar, MoS, Health had informed media.

Also Read :

Bharat Biotech Awaits Feedback From WHO For Covaxin’s Emergency Use Listing

According to Bharat Biotech Covaxin Phase 3 clinical trials of Covaxin demonstrated an efficacy rate of 77.8 per cent.

Bharat Biotech had also informed that the company has responded to clarifications sought by WHO and is awaiting further feedback.

“As a responsible manufacturer with several pre-qualified vaccines, we do not find it appropriate to speculate or comment on the approval process and its timelines,” a statement from Bharat Biotech informed.

Speaking to ANI, Chairman of the National Expert Committee on Vaccine Administration and Member of Health for NITI Aayog Dr VK Paul had also said that the WHO’s approval for Bharat Biotech’s COVID-19 vaccine, Covaxin, is likely to come before the end of this month.

The strategic advisory group of experts on Immunization (SAGE) of the WHO will be meeting in October to make its recommendations on Bharat Biotech’s COVID-19 vaccine Covaxin on EUL.

Tags: AstraZenecaBharat BiotechCovaxinCovishieldEmergency Use ListingeulwhoWorld Health Organisation
ShareTweetSendShareSend

Latest News

NIA files chargesheet against 4 people in fake currency, gold seizure case

Daryl Mitchell becomes first NZ player to smash three successive centuries against England in a Test series

Haryana: Chess Olympiad Torch Relay reaches Gurugram

Life-saving relief continues to reach quake-hit eastern Afghanistan

Uyghur American elected as chairman of US Commission on International Religious Freedom

Xi Jinping to visit Hong Kong, his first trip outside China since COVID began

China reports 7 new local COVID-19 cases

Mira Kapoor shares a glimpose of her vacation through a string of images

USD2.3 bn Chinese loan credited to State Bank of Pakistan: Finance Minister Miftah Ismail

CM Patnaik shares Odisha’s achievements on food security at WFP headquarters in Rome

New Delhi : The World Health Organisation (WHO) on Wednesday informed that the final decision on Bharat Biotech's submission on emergency use listing (EUL) for its Covaxin COVID-19 vaccine will be made in October 2021. The status of assessment for Covaxin is "ongoing" as of now, the WHO informed in a document citing the status of COVID vaccines. On the WHO website, the decision date for Bharat Biotech's Covaxin is October 2021. Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine. The duration of the emergency use listing process depends on the quality of the data which is submitted by the vaccine manufacturer. The WHO has also asked for additional data from Bharat Biotech for Covaxin, sources from the WHO informed media. "There is a procedure of submitting the documents for approval, WHO's emergency use authorization to Covaxin is expected soon," Dr Bharati Pravin Pawar, MoS, Health had informed media. Also Read : Bharat Biotech Awaits Feedback From WHO For Covaxin’s Emergency Use Listing According to Bharat Biotech Covaxin Phase 3 clinical trials of Covaxin demonstrated an efficacy rate of 77.8 per cent. Bharat Biotech had also informed that the company has responded to clarifications sought by WHO and is awaiting further feedback. "As a responsible manufacturer with several pre-qualified vaccines, we do not find it appropriate to speculate or comment on the approval process and its timelines," a statement from Bharat Biotech informed. Speaking to ANI, Chairman of the National Expert Committee on Vaccine Administration and Member of Health for NITI Aayog Dr VK Paul had also said that the WHO's approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is likely to come before the end of this month. The strategic advisory group of experts on Immunization (SAGE) of the WHO will be meeting in October to make its recommendations on Bharat Biotech's COVID-19 vaccine Covaxin on EUL.
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science